Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 1
2003 1
2005 1
2006 3
2007 2
2008 4
2010 1
2011 2
2012 1
2013 1
2014 1
2016 1
2017 2
2019 1
2020 1
2021 1
2022 1
2024 2
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gión M, Guarneri V, Bianchini G, Wildiers H, Escrivá-de-Romaní S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Harbeck N, et al. Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13. Nat Med. 2024. PMID: 39271844 Free PMC article. Clinical Trial.
International consensus on fasting terminology.
Koppold DA, Breinlinger C, Hanslian E, Kessler C, Cramer H, Khokhar AR, Peterson CM, Tinsley G, Vernieri C, Bloomer RJ, Boschmann M, Bragazzi NL, Brandhorst S, Gabel K, Goldhamer AC, Grajower MM, Harvie M, Heilbronn L, Horne BD, Karras SN, Langhorst J, Lischka E, Madeo F, Mitchell SJ, Papagiannopoulos-Vatopaidinos IE, Papagiannopoulou M, Pijl H, Ravussin E, Ritzmann-Widderich M, Varady K, Adamidou L, Chihaoui M, de Cabo R, Hassanein M, Lessan N, Longo V, Manoogian ENC, Mattson MP, Muhlestein JB, Panda S, Papadopoulou SK, Rodopaios NE, Stange R, Michalsen A. Koppold DA, et al. Cell Metab. 2024 Aug 6;36(8):1779-1794.e4. doi: 10.1016/j.cmet.2024.06.013. Epub 2024 Jul 25. Cell Metab. 2024. PMID: 39059384 Free PMC article.
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A; NALA Investigators. Saura C, et al. J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17. J Clin Oncol. 2020. PMID: 32678716 Free PMC article. Clinical Trial.
METHODS: Patients, including those with stable, asymptomatic CNS disease, were randomly assigned 1:1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m(2) twice a day 14 d/21 d) with loperamide prophylaxis, or to lapatinib (1,250 mg once every day) plu …
METHODS: Patients, including those with stable, asymptomatic CNS disease, were randomly assigned 1:1 to neratinib (240 mg once every day) pl …
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women.
Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A, Howell A. Harvie MN, et al. Int J Obes (Lond). 2011 May;35(5):714-27. doi: 10.1038/ijo.2010.171. Epub 2010 Oct 5. Int J Obes (Lond). 2011. PMID: 20921964 Free PMC article. Clinical Trial.
DESIGN: Randomized comparison of a 25% energy restriction as IER ( 2710 kJ/day for 2 days/week) or CER ( 6276 kJ/day for 7 days/week) in 107 overweight or obese (mean ( s.d.) body mass index 30.6 ( 5.1) kg m(-2)) premenopausal women observed over a period of 6 months. …
DESIGN: Randomized comparison of a 25% energy restriction as IER ( 2710 kJ/day for 2 days/week) or CER ( 6276 kJ/day for 7 days/week) in 1 …
A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.
Cleary KLS, Semmrich M, Martensson L, Tornberg UC, Ermert D, Taylor MC, Oldham RJ, Dadas O, Buckingham JF, Kim J, Chan HTC, Palm A, Fischer AH, Boden M, Mattsson J, Holmkvist P, Lim SH, Beers SA, Frendeus B, Teige I, Cragg MS. Cleary KLS, et al. Cancer Immunol Res. 2025 Dec 2;13(12):1969-1986. doi: 10.1158/2326-6066.CIR-24-1083. Cancer Immunol Res. 2025. PMID: 41003662 Free PMC article.
Neurobehavioral consequences of prenatal alcohol exposure: an international perspective.
Riley EP, Mattson SN, Li TK, Jacobson SW, Coles CD, Kodituwakku PW, Adnams CM, Korkman MI. Riley EP, et al. Alcohol Clin Exp Res. 2003 Feb;27(2):362-73. doi: 10.1097/01.ALC.0000052703.38558.B2. Alcohol Clin Exp Res. 2003. PMID: 12605086
Jacobson, Christopher D. Molteno, Denis Viljoen, and Joseph L. Jacobson; (2) A pilot study of classroom intervention for learners with fetal alcohol syndrome in South Africa, by Colleen Adnams, M. ...W. Kodituwakku, W. Kalberg, L. Robinson, and P. A. May; (4) …
Jacobson, Christopher D. Molteno, Denis Viljoen, and Joseph L. Jacobson; (2) A pilot study of classroom intervention for learn …
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.
Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schüler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkilä P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefström J. Haikala HM, et al. Nat Commun. 2019 Feb 6;10(1):620. doi: 10.1038/s41467-019-08541-2. Nat Commun. 2019. PMID: 30728358 Free PMC article.
We find, in a model of MYC-driven breast cancer, that pharmacological activation of AMPK strongly synergizes with BCL-2/BCL-X(L) inhibitors to activate apoptosis. We demonstrate the translational potential of an AMPK and BCL-2/BCL-X(L) co-targeting strategy in ex vi …
We find, in a model of MYC-driven breast cancer, that pharmacological activation of AMPK strongly synergizes with BCL-2/BCL-X(L) inhi …
The astrocytic transporter SLC7A10 (Asc-1) mediates glycinergic inhibition of spinal cord motor neurons.
Ehmsen JT, Liu Y, Wang Y, Paladugu N, Johnson AE, Rothstein JD, du Lac S, Mattson MP, Höke A. Ehmsen JT, et al. Sci Rep. 2016 Oct 19;6:35592. doi: 10.1038/srep35592. Sci Rep. 2016. PMID: 27759100 Free PMC article.
SLC7A10 (Asc-1) is a sodium-independent amino acid transporter known to facilitate transport of a number of amino acids including glycine, L-serine, L-alanine, and L-cysteine, as well as their D-enantiomers. It has been described as a neuronal transpor …
SLC7A10 (Asc-1) is a sodium-independent amino acid transporter known to facilitate transport of a number of amino acids including glycine, …
27 results